Loading stock data…
MGNX
$3.45-0.07 (-1.99%)
Market ClosedLast close May 13
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MacroGenics, Inc. in the Healthcare sector is trading at $3.45. Wall Street consensus targets $6.00 (4 analysts), implying a +73.9% move over the next 12 months. The stock is currently near its 52-week high of $3.88, remaining 71.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +73.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$3.45
Potential Downside
0%
Whystock Fair Value$3.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$205.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-86.94%
Volume
Today's trading volume
1.51M
Recent News
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -1.75% and +12.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investments still offer potential value by focusing on smaller or newer companies with strong financials. In this article, we explore three penny stocks that demonstrate financial strength and could present opportunities for investors seeking hidden value in quality companies.
GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)
MacroGenics agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals in a deal designed to strengthen its balance sheet and sharpen focus on its oncology pipeline. Key Investor TakeawaysMacroGenics (NASDAQ:MGNX) will receive $122.
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of -32.48% and +1.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.